|
1
|
DeSantis CE, Fedewa SA, Sauer A Goding,
Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015:
Convergence of incidence rates between black and white women. CA
Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arnedos M, Vicier C, Loi S, Lefebvre C,
Michiels S, Bonnefoi H and Andre F: Precision medicine for
metastatic breast cancer - limitations and solutions. Nat Rev Clin
Oncol. 12:693–704. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lamouille S, Xu J and Derynck R: Molecular
mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell
Biol. 15:178–196. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baranwal S and Alahari SK: Molecular
mechanisms controlling E-cadherin expression in breast cancer.
Biochem Biophys Res Commun. 384:6–11. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McConkey DJ, Choi W, Marquis L, Martin F,
Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al: Role
of epithelial-to-mesenchymal transition (EMT) in drug sensitivity
and metastasis in bladder cancer. Cancer Metastasis Rev.
28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu L, Zhang L, Hu C, Liang S, Fei X, Yan
N, Zhang Y and Zhang F: WNT pathway inhibitor pyrvinium pamoate
inhibits the self-renewal and metastasis of breast cancer stem
cells. Int J Oncol. 48:1175–1186. 2016.PubMed/NCBI
|
|
13
|
Ross JA and Kasum CM: Dietary flavonoids:
Bioavailability, metabolic effects, and safety. Annu Rev Nutr.
22:19–34. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin Y, Shi R, Wang X and Shen HM:
Luteolin, a flavonoid with potential for cancer prevention and
therapy. Curr Cancer Drug Targets. 8:634–646. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen CY, Peng WH, Tsai KD and Hsu SL:
Luteolin suppresses inflammation-associated gene expression by
blocking NF-kappaB and AP-1 activation pathway in mouse alveolar
macrophages. Life Sci. 81:1602–1614. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chung JG, Hsia TC, Kuo HM, Li YC, Lee YM,
Lin SS and Hung CF: Inhibitory actions of luteolin on the growth
and arylamine N-acetyltransferase activity in strains of
Helicobacter pylori from ulcer patients. Toxicol In Vitro.
15:191–198. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Du Y, Feng J, Wang R, Zhang H and Liu J:
Effects of flavonoids from Potamogeton crispus L. on proliferation,
migration, and invasion of human ovarian cancer cells. PLoS One.
10:e01306852015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma L, Peng H, Li K, Zhao R, Li L, Yu Y,
Wang X and Han Z: Luteolin exerts an anticancer effect on NCI-H460
human non-small cell lung cancer cells through the induction of
Sirt1-mediated apoptosis. Mol Med Rep. 12:4196–4202.
2015.PubMed/NCBI
|
|
19
|
Shi R, Huang Q, Zhu X, Ong YB, Zhao B, Lu
J, Ong CN and Shen HM: Luteolin sensitizes the anticancer effect of
cisplatin via c-Jun NH2-terminal kinase-mediated p53
phosphorylation and stabilization. Mol Cancer Ther. 6:1338–1347.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang MY, Wang CJ, Chen NF, Ho WH, Lu FJ
and Tseng TH: Luteolin enhances paclitaxel-induced apoptosis in
human breast cancer MDA-MB-231 cells by blocking STAT3. Chem Biol
Interact. 213:60–68. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tu SH, Ho CT, Liu MF, Huang CS, Chang HW,
Chang CH, Wu CH and Ho YS: Luteolin sensitises drug-resistant human
breast cancer cells to tamoxifen via the inhibition of cyclin E2
expression. Food Chem. 141:1553–1561. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cook MT, Liang Y, Besch-Williford C,
Goyette S, Mafuvadze B and Hyder SM: Luteolin inhibits
progestin-dependent angiogenesis, stem cell-like characteristics,
and growth of human breast cancer xenografts. Springerplus.
4:4442015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao C, Qiao Y, Jonsson P, Wang J, Xu L,
Rouhi P, Sinha I, Cao Y, Williams C and Dahlman-Wright K:
Genome-wide profiling of AP-1-regulated transcription provides
insights into the invasiveness of triple-negative breast cancer.
Cancer Res. 74:3983–3994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Voduc KD, Cheang MCU, Tyldesley S, Gelmon
K, Nielsen TO and Kennecke H: Breast cancer subtypes and the risk
of local and regional relapse. J Clin Oncol. 28:1684–1691. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carey L, Winer E, Viale G, Cameron D and
Gianni L: Triple-negative breast cancer: Disease entity or title of
convenience? Nat Rev Clin Oncol. 7:683–692. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vuoriluoto K, Haugen H, Kiviluoto S,
Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J:
Vimentin regulates EMT induction by Slug and oncogenic H-Ras and
migration by governing Axl expression in breast cancer. Oncogene.
30:1436–1448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chung S, Yao J, Suyama K, Bajaj S, Qian X,
Loudig OD, Eugenin EA, Phillips GR and Hazan RB: N-cadherin
regulates mammary tumor cell migration through Akt3 suppression.
Oncogene. 32:422–430. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Huang X, Dai S, Dai J, Xiao Y, Bai Y, Chen
B and Zhou M: Luteolin decreases invasiveness, deactivates STAT3
signaling, and reverses interleukin-6 induced
epithelial-mesenchymal transition and matrix metalloproteinase
secretion of pancreatic cancer cells. Onco Targets Ther.
8:2989–3001. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
de Herreros AG, Peiró S, Nassour M and
Savagner P: Snail family regulation and epithelial mesenchymal
transitions in breast cancer progression. J Mammary Gland Biol
Neoplasia. 15:135–147. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dey N, Barwick BG, Moreno CS,
Ordanic-Kodani M, Chen Z, Oprea-Ilies G, Tang W, Catzavelos C,
Kerstann KF, Sledge GW Jr, et al: Wnt signaling in triple negative
breast cancer is associated with metastasis. BMC Cancer.
13:5372013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Geyer FC, Lacroix-Triki M, Savage K,
Arnedos M, Lambros MB, MacKay A, Natrajan R and Reis-Filho JS:
β-Catenin pathway activation in breast cancer is associated with
triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol.
24:209–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sánchez-Tilló E, de Barrios O, Siles L,
Cuatrecasas M, Castells A and Postigo A: β-catenin/TCF4 complex
induces the epithelial-to-mesenchymal transition (EMT)-activator
ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA.
108:19204–19209. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG and
Weiss SJ: Canonical Wnt signaling regulates Slug activity and links
epithelial-mesenchymal transition with epigenetic Breast Cancer 1,
Early Onset (BRCA1) repression. Proc Natl Acad Sci USA.
109:16654–16659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yook JI, Li XY, Ota I, Hu C, Kim HS, Kim
NH, Cha SY, Ryu JK, Choi YJ, Kim J, et al: A Wnt-Axin2-GSK3beta
cascade regulates Snail1 activity in breast cancer cells. Nat Cell
Biol. 8:1398–1406. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ashokkumar P and Sudhandiran G: Luteolin
inhibits cell proliferation during Azoxymethane-induced
experimental colon carcinogenesis via Wnt/β-catenin pathway. Invest
New Drugs. 29:273–284. 2011. View Article : Google Scholar : PubMed/NCBI
|
